ICAM1 and neoplasm: Park et al. reported that the chimeric antigen receptor (CAR)-T cells with mM affinity to intercellular adhesion molecule-1 (ICAM-1) only attacked tumor cells with high levels of ICAM-1, and achieved more rapid tumor elimination and more safety than the CAR-T cells with nM affinity to ICAM-1 [48].